Literature DB >> 17124072

Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells.

Nicholas Chiorazzi1, Manlio Ferrarini.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) has long been considered a disease of "accumulation," due to a presumed defect in programmed cell death. Recent data, however, suggest that B-CLL cells are born at a normal to an accelerated rate, with the rate of proliferation varying among patients. In addition, differences in birth rates, activation state, and inducibility appear to exist among subpopulations of cells within individual leukemic clones. The extent to which such dissimilarities influence clinical course and outcome is still unclear. This review examines the evidence supporting the existence of a proliferative compartment in B-CLL and the role that proliferating cells might play in the progression and evolution of this disease.

Entities:  

Mesh:

Year:  2006        PMID: 17124072     DOI: 10.1182/asheducation-2006.1.273

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  9 in total

Review 1.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

2.  CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.

Authors:  Erika Tissino; Federico Pozzo; Dania Benedetti; Chiara Caldana; Tamara Bittolo; Francesca Maria Rossi; Riccardo Bomben; Paola Nanni; Hillarj Chivilò; Ilaria Cattarossi; Eva Zaina; Kevin Norris; Jerry Polesel; Massimo Gentile; Giovanni Tripepi; Riccardo Moia; Enrico Santinelli; Idanna Innocenti; Jacopo Olivieri; Giovanni D'Arena; Luca Laurenti; Francesco Zaja; Gabriele Pozzato; Annalisa Chiarenza; Francesco Di Raimondo; Davide Rossi; Chris Pepper; Tanja Nicole Hartmann; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei; Antonella Zucchetto
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

3.  Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.

Authors:  Byeongho Jung; Gerardo Ferrer; Pui Yan Chiu; Rukhsana Aslam; Anita Ng; Florencia Palacios; Michael Wysota; Martina Cardillo; Jonathan E Kolitz; Steven L Allen; Jacqueline C Barrientos; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal:  JCI Insight       Date:  2022-06-22

4.  Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia.

Authors:  Michael Asger Andersen; Mia Klinten Grand; Christian Brieghel; Volkert Siersma; Christen Lykkegaard Andersen; Carsten Utoft Niemann
Journal:  Commun Med (Lond)       Date:  2022-05-12

5.  Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.

Authors:  Vanessa Fonseca Tumilasci; Stephanie Olière; Thi Lien-Ahn Nguyên; April Shamy; John Bell; John Hiscott
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.

Authors:  Wei Ding; Grzegorz S Nowakowski; Traci R Knox; Justin C Boysen; Mary L Maas; Susan M Schwager; Wenting Wu; Linda E Wellik; Allan B Dietz; Asish K Ghosh; Charla R Secreto; Kay L Medina; Tait D Shanafelt; Clive S Zent; Timothy G Call; Neil E Kay
Journal:  Br J Haematol       Date:  2009-09-08       Impact factor: 6.998

7.  At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Ji Yuan Wu; Srdana Grgurevic; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Matthew Martinez; Srdan Verstovsek; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2016-04-13       Impact factor: 5.422

8.  Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia.

Authors:  Ksenija Vucicevic; Vladimir Jakovljevic; Natasa Colovic; Natasa Tosic; Tatjana Kostic; Irena Glumac; Sonja Pavlovic; Teodora Karan-Djurasevic; Milica Colovic
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

9.  STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan Burger; Phillip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Oncotarget       Date:  2018-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.